secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2025-03-05T23:59:59+00:00
Accession:  0000950170-25-033075
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Director Tomas Kiselak resigns; Sujay Kango appointed to board and compensation committee
--------------------------------------------------------------------------------

- Tomas Kiselak resigned from Dianthus Therapeutics board effective March 4, 2025; no disagreement cited.
- Sujay Kango appointed as Class II director and member of Compensation Committee, effective March 4, 2025.
- Kango receives initial option grant of 25,000 shares vesting over three years; cash compensation of $40,000/yr (board) and $6,000/yr (committee).
- Kango will enter into a standard indemnification agreement with the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000095017025033075/0000950170-25-033075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000095017025033075/dnth-20250304.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-033075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer